[EN] ARYL- AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE [FR] DÉRIVÉS ARYLECARBONYLE ET HÉTÉROARYLCARBONYLE D'HEXAHYDROINDÉNOPYRIDINE ET D'OCTAHYDROBENZOQUINOLINE
ARYL-AND HETEROARYLCARBONYL DERIVATIVES OF HEXAHYDROINDENOPYRIDINE AND OCTAHYDROBENZOQUINOLINE
申请人:Eckhardt Matthias
公开号:US20110136800A1
公开(公告)日:2011-06-09
The present invention relates to compounds defined by formula I
wherein the variables R
1
, R
2
, R
3
, R
4
, and m are defined as in claim
1
, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.
[EN] CRYSTALLINE FORMS OF HYDROCHLORIDE SALT OF (4A-R,9A-S) -1- (1H - BENZOIMIDAZOLE- 5 -CARBONYL) -2, 3, 4, 4A, 9, 9A - HEXAHYDRO -1H- INDENO [2, 1 -B] PYRIDINE- 6 -CARBONITRILE AND THEIR USE AS HSD 1 INHIBITORS<br/>[FR] FORMES CRISTALLINES DU SEL DE TYPE CHLORHYDRATE DU (4A-R,9A-S)-1-(1H-BENZIMIDAZOLE-5-CARBONYL)-2,3,4,4A,9,9A-HEXAHYDRO-1H-INDÉNO[2,1-B]PYRIDINE-6-CARBONITRILE ET LEUR UTILISATION COMME INHIBITEURS D'HSD1
申请人:BOEHRINGER INGELHEIM INT
公开号:WO2012061708A1
公开(公告)日:2012-05-10
The present invention relates to crystalline compounds of the following structural formula (II) possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11 β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.
The present invention relates to compounds defined by formula I
wherein the variables R
1
, R
2
, R
3
, R
4
, and m are defined as in claim
1
, possessing valuable pharmacological activity. Particularly, the compounds are inhibitors of 11β-hydroxysteroid dehydrogenase (HSD) 1 and thus are suitable for treatment and prevention of diseases which can be influenced by inhibition of this enzyme, such as metabolic diseases, in particular diabetes type 2, obesity, and dyslipidemia.